
TBPH P/E Ratio
P/E Ratio as of Oct 2, 2026: 16.87
Average16.88
Median16.87
Minimum16.85
Maximum16.92
16.87
0.05 (0.30%)past month
The P/E ratio for TBPH is 16.87 as of Oct 2, 2026. This represents a decrease of -26.01% compared to its 12-month average P/E ratio of 22.8. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Theravance Biopharma Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Theravance Biopharma Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Theravance Biopharma Inc to industry peers.
Theravance Biopharma Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Theravance Biopharma Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Theravance Biopharma Inc to industry peers.
TBPH P/E Ratio Insights
See Theravance Biopharma Inc’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in TBPH
Order type
Buy in
Order amount
Est. shares
0 shares
TBPH P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | — | 16.87 |
| Sep 1, 2026 | $17.03 | 16.87 |
| Aug 3, 2026 | $16.87 | 7.65 |
| Jul 1, 2026 | $16.98 | 7.70 |
| Jun 1, 2026 | $15.94 | 7.23 |
| May 1, 2026 | $16.79 | 8.28 |
| Apr 1, 2026 | $15.84 | 7.81 |
| Mar 2, 2026 | $18.95 | 33.69 |
| Feb 2, 2026 | $19.83 | 35.25 |
| Jan 2, 2026 | $18.15 | 32.27 |
TBPH End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | 16.87 | -49.28% |
| 2025 | 33.26 | -457.63% |
| 2024 | -9.30 | -21.25% |
| 2023 | -11.81 | +305.84% |
| 2022 | -2.91 | -22.40% |
| 2021 | -3.75 | — |
FAQs About Theravance Biopharma Inc (TBPH) P/E ratio
The latest P/E ratio of TBPH is 16.87, as of Oct 2, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Theravance Biopharma Inc’s last 12-month average P/E ratio is 22.8, compared to its current P/E ratio of 16.87. This reflects a decrease of -26.01%.
Theravance Biopharma Inc’s current P/E ratio of 16.87 is lower than its last 12-month average P/E of 22.8. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Theravance Biopharma Inc’s average P/E ratio over the last 3 years is 5.16. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Theravance Biopharma Inc’s average P/E ratio over the last 5 years is 1.54. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.